SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

vTv Therapeutics Randomizes First Participant in Phase 2a Study

vTv Therapeutics randomized the first participant in its Phase 2a cadisegliatin study for type 1 diabetes.

VTVT

Related stories